GILD

As of 2026-09-10, GILD scores 51out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. GILD trades at $145.65, within its fair-value band.

GILD scores 51 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 51. Its strongest factor is value at 82 (exceptional), where it screens cheap on the model's valuation inputs, followed by sentiment at 56. The weakest is quality at 33, where earnings-quality metrics lag. Among Healthcare stocks it ranks in roughly the top 28% of the Healthcare names the model scores.

On valuation, GILD is priced near the floor of its own recent range — the cheap end on the model's valuation read. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 52. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on GILD, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where GILD sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for GILD runs $140.76–$183.16. Current price $145.65 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.